Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared a post on X:
“A meta-analysis from the DADSPORT Collaboration:
Adding hormone therapy to post-op radiotherapy in nonmetastatic prostate cancer improves:
Metastasis-free survival (HR=0.78)
Prostate cancer–specific survival (HR=0.61)
Overall survival benefit small (HR=0.86), limited to high-risk patients.
Title: Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Authors: Sarah Burdett, David J. Fisher, Jayne F. Tierney, Adrian D. Cook, Daniel E. Spratt, James J. Dignam, Wendy F. Seiferheld, Amar U. Kishan, Yilun Sun, Sylvie Chabaud, Jason A. Efstathiou, Christopher C. Parker, Alan Pollack, Paul Sargos, Igor Latorzeff, Meryem Brihoum, Charles N. Catton, Noel W. Clarke, Felix Y. Feng, Theodore G. Karrison, Pascal Pommier, Howard M. Sandler, Matthew R. Sydes, Claire L. Vale
You can read the Full Article on Elsevier
More posts featuring Emre Yekedüz.